Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide for Cognitive Improvement in Down Syndrome
NCT06465823Phase 2Recruiting
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Down syndrome comparing Bumetanide with Placebo (2 arms). Primary endpoint: Visual-Object long-term memory measures at 5 months. Started Jan 2023; status: recruiting.
02
Drugs
bumetanide
03
Conditions
Down syndrome
Beyond the preview
Go deeper on NCT06465823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06465823.